ERBB2 and breast lobular carcinoma: The underlying CDK12/HER2 gene coamplification, which is substantially detectable in our HER2‐positive lobular breast carcinoma cohort, is a characteristic molecular phenomenon in this subgroup, possibly contributing to poor prognostic behavior.